Sudarshan Pharma Industries extended its winning streak to three consecutive sessions, with shares rallying 10% to hit the upper circuit today. According to reports from ET Now, the stock opened with a gap up of more than 7% at ₹22.60 and extended gains to reach the day's upper price band of ₹23.10. Trading on the counter was subsequently halted after hitting the upper circuit limit. As per Samco, the stock locked in its 10% upper circuit at ₹23.10 on Thursday, February 5, marking the second consecutive day of hitting an upper circuit after already hitting a 5% upper circuit at ₹21 the previous day on February 4.
The company delivered strong financial results for the third quarter of FY26, as reported by ET Now. Net sales increased by 16% year-on-year to ₹168 crore, while net profit surged by more than 50% YoY to ₹4.36 crore. For the nine-month period ending December 2025, net sales climbed 40% to ₹482.14 crore and net profit advanced 67% to ₹12.58 crore. The latest quarterly performance shows up 16% year-on-year compared with Q3FY25 and jumped 51% from the same quarter last year, demonstrating consistent growth momentum across multiple reporting periods.
In a strategic move to strengthen its international presence, Sudarshan Pharma recently incorporated a wholly owned subsidiary, Sudarshan Pharma Company Poland Limited Liability, as reported by ET Now. The subsidiary, headquartered in Warsaw, Poland, received board approval in February 2025 with an investment amount of PLN 5,000 and 100% equity stake. The subsidiary will focus on manufacturing chemicals, fertilisers, and plastics, along with wholesale distribution of pharmaceutical products across European markets. This expansion aims to support the company's growth in the global chemical and agrochemical space.
Despite the strong performance, Sudarshan Pharma has faced significant challenges over the past year, with the stock down over 40% in the last 1 year, down 24% in the last 6 months, and down 19% in the last 3 months, as reported by Samco. The current rally stands out even more against this backdrop of sustained pressure. The stock has now logged over 17% rise in just 3 trading sessions, demonstrating remarkable resilience as the benchmark indices like Sensex and Nifty 50 slipped nearly 0.5% on Thursday, tracking weak global cues and ongoing concerns around AI-led disruptions in global technology markets.
From a technical perspective, according to ET Now, the stock is trading higher than 5-day and 20-day moving averages but lower than 50-day, 100-day and 200-day moving averages. The company operates across multiple segments including jobwork manufacturing for pharmaceutical products, trading in chemicals and solvents within India, and presence in the speciality chemicals business. As per BSE analytics, the stock has underperformed the broader markets in the last year, slipping 10% as against 6% rise in the BSE Sensex. The company's diversified operational base forms the core of its business activities across pharmaceutical products, chemicals, and speciality chemicals.
As reported by ET Now, the promoters own a majority stake of 57.39% in the company, while FIIs hold 19.78% stake. The remaining shareholding is distributed among DIIs and non-institutional investors. The company had launched its IPO in March 2023 at ₹73 per share and approved a corporate action for stock split in November 2024 in the ratio of 10:1, reducing the face value from ₹10 to Re 1 each.
